Medical Technology

The Mandate

A Shenzhen-based integrated medical and aesthetic devices group — 1,300+ employees, five manufacturing sites, products used in 85% of China's major hospitals — was evaluating a strategic investment in an Israeli pre-clinical laser technology company, including potential acquisition, minority investment, or distribution partnership. The startup's technology presented a strategic fit for the client's planned expansion into the US market.

Our Approach

We coordinated the full due diligence process on the client's behalf, assembling and managing a team of relevant local experts — scientific, intellectual property, and commercial — to assess the technology, its IP position, and its commercial readiness. This was carried out in close coordination with a leading Israeli medical investment fund, ensuring the client's read on execution risk and strategic fit was grounded in independent, specialist input rather than a single outside opinion.

The Challenge

The real challenge was less about the technology and more about competitive positioning on both sides of the table. The startup had other, better-known venture investors circling the same opportunity, so the client needed a credible way to stand out — not just as a source of capital, but as the right long-term partner for a pre-clinical company entering its next stage of growth. At the same time, as a Chinese acquirer relatively unknown within the Israeli venture ecosystem, the client had its own trust and credibility to establish. The turning point was reframing the conversation: rather than competing purely on valuation, we helped articulate the client's unique advantages — its existing distribution across 85% of China's major hospitals, its in-house manufacturing capacity, and its stated ambition to expand into the US — as a fit no financial investor could match.